ClinicalTrials.gg
Active, not recruitingNCT06491914ELARAUpdated Sep 18, 2026Results posted

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

A Phase 3 interventional study of Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 54 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-18.

Primary conditionMacular EdemaRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Macular Edema
Why
  1. The study's listed conditions name Macular Edema, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,126
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
Largest of 53
1,126 · median 49
Started
2024
with 4 others
Phase 3
11 of 53
none open now
Registered
50th of 53
by date
Lead sponsor
6 of 53
Regeneron Pharmaceuticals

Among the 53 studies testing aflibercept in Macular Edema, this one has the largest enrollment, is one of 5 that started in 2024, is one of 11 in phase 3, and was the 50th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

This study is researching aflibercept high dose (HD), referred to as "study drug", with an experimental dosing regimen. The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications.

The aim of the study is to see how safe and effective aflibercept HD injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration
  • Diabetic Macular Edema

Browse trials for

04

In context

Macular Edema Reclassified

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

This study's enrollment of 1,126 is above the median of 56 across 586 interventional studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria for Participants with nAMD:

  1. ≥50 years of age
  2. History of choroidal neovascularization (CNV) lesions secondary to nAMD in the eye study, requiring continued anti-VEGF treatment, as determined by the investigator.

    Key Inclusion Criteria for Participants with DME:

  3. ≥18 years of age
  4. History of DME with central involvement (in the central subfield on Spectral domain optical coherence tomography [SD-OCT]) in the study eye, requiring continued anti-VEGF treatment, as determined by the investigator

    Key Inclusion for All Participants:

  5. Previously treated with ≥3 anti-VEGF IVT injections in the study eye in the 5 months (\~150 days) prior to visit 1

Key Exclusion Criteria for Participants with nAMD:

  1. Evidence of CNV due to any cause other than nAMD in either eye

    Key Exclusion Criteria for Participants with DME:

  2. Evidence of macular edema due to any other cause other than diabetes mellitus in the study eye
  3. Active proliferative diabetic retinopathy (DR) in the study eye

NOTE: Other protocol defined inclusion / exclusion criteria apply.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,126 participants (actual)

Study arms

  • Experimental
    Aflibercept 8 mg

    Participants previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications

    Drug: Aflibercept 8 mg

Interventions

  • Administered by intravitreal (IVT) injection

    Also known as: EYLEA®HD, BAY86-5321

07

What researchers measure

Primary outcomes

  1. Participants With at Least One Treatment-emergent Adverse Event (TEAE)

    Time frame: Through week 24

  2. Participants With at Least One Serious TEAE

    Time frame: Through week 24

08

Results

Posted Sep 18, 2026
Limitations and caveats
Due to non-compliance issues, 16 participants were not included in the baseline characteristics and outcome measure analyses. The 16 participants were included in adverse event reporting.

Participant flow

1376 participants screened. 1126 participants enrolled. 1110 participants treated.

Participant flow — Overall Study
MilestoneNeovascular Age-related Macular DegenerationDiabetic Macular Edema
Started625501
Enrolled and treated622488
Completed595471
Not completed3030
Withdrew: Adverse event43
Withdrew: Death22
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject2010
Withdrew: Non-compliance313

Outcome measures

PrimaryParticipants With at Least One Treatment-emergent Adverse Event (TEAE)
Time frame:
Through week 24
Reported as:
Number · percentage
Participants With at Least One Treatment-emergent Adverse Event (TEAE)
percentageNeovascular Age-related Macular DegenerationDiabetic Macular Edema
Ocular Treatment-Emergent Adverse Events - Study Eye17.022.3
Ocular Treatment-Emergent Adverse Events - Fellow Eye13.016.4
Non-ocular Treatment-Emergent Adverse Events36.839.3
PrimaryParticipants With at Least One Serious TEAE
Time frame:
Through week 24
Reported as:
Number · percentage
Participants With at Least One Serious TEAE
percentageNeovascular Age-related Macular DegenerationDiabetic Macular Edema
Ocular Treatment-Emergent Serious Adverse Events - Study Eye0.20.8
Ocular Treatment-Emergent Serious Adverse Events - Fellow Eye0.30.2
Non-ocular Treatment-Emergent Serious Adverse Events5.07.2

Adverse events

Collected over From the date of informed consent (ICF) signature through Week 24.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Neovascular Age-related Macular Degeneration2/625 (0.3%)34/625 (5.4%)0/625 (0%)
Diabetic Macular Edema4/501 (0.8%)40/501 (8%)0/501 (0%)
Most frequent serious events
Showing 10 of 82
Most frequent serious events
EventNeovascular Age-related Macular DegenerationDiabetic Macular Edema
Cerebrovascular accidentNervous system disorders1/6253/501
AnaemiaBlood and lymphatic system disorders0/6253/501
Endophthalmitis Study EyeInfections and infestations0/6253/501
SyncopeNervous system disorders0/6252/501
Transient ischaemic attackNervous system disorders0/6252/501
Acute kidney injuryRenal and urinary disorders1/6252/501
Acute myocardial infarctionCardiac disorders1/6252/501
Myocardial infarctionCardiac disorders2/6252/501
DeathGeneral disorders0/6252/501
Mental status changesPsychiatric disorders0/6252/501

Baseline characteristics

All enrolled participants who received at least 1 injection of aflibercept during the study were included. Due to non-compliance issues, 16 participants were not included in the baseline characteristics and outcome measure analyses. Only 1 eye per participant was enrolled as the "study eye." The non-study eye is then considered as the "fellow eye."

Age, Continuous
Age, Continuous(years)Neovascular Age-related Macular DegenerationDiabetic Macular EdemaTotal
Mean77.1 ± 8.562.8 ± 9.870.8 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Neovascular Age-related Macular DegenerationDiabetic Macular EdemaTotal
Female360203563
Male262285547
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Neovascular Age-related Macular DegenerationDiabetic Macular EdemaTotal
Hispanic or Latino43114157
Not Hispanic or Latino566371937
Unknown or Not Reported13316
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Neovascular Age-related Macular DegenerationDiabetic Macular EdemaTotal
American Indian or Alaska Native022
Asian213859
Native Hawaiian or Other Pacific Islander101
Black or African American85159
White589387976
More than one race112
Unknown or Not Reported2911
09

Study locations

54 sites
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued developed of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Aug 2025, 13 months.

Results were first posted in Sep 2026, 1 year after primary completion.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 13 months is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 9, 2024
StartActual
Jul 24, 2024
Primary completionActual
Aug 26, 2025
CompletionEst.
Jan 7, 2027
Results first posted
Sep 18, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT06491914
Responsible party
Sponsor
First posted
Jul 9, 2024
Start date
Jul 24, 2024
Primary completion
Aug 26, 2025
Completion
Jan 7, 2027 (estimated)
Results posted
Sep 18, 2026
Last update
Sep 18, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion